Chad Moretz, ScD

Articles by Chad Moretz, ScD

Medical Policy Determinations for Pharmacogenetic Tests Among US Health Plans

ByJai N. Patel, PharmD,Lena Chaihorsky, BS,Olivia M. Dong, PhD,Christine Y. Lu, PhD,Chad Moretz, ScD,Emily Reese, PhD, MPH,Wrenda Teeple, PharmD,Benjamin Brown, BS,Sara Rogers, PharmD

February 10th 2025

This analysis demonstrated significant variability in medical policy determinations and evidence cited for clinically relevant pharmacogenetic tests among major US health insurers and laboratory benefit managers.

Relationship of Diabetes Complications Severity to Healthcare Utilization and Costs Among Medicare Advantage Beneficiaries

ByLeslie Hazel-Fernandez, PhD, MPH,Yong Li, PhD,Damion Nero, PhD,Chad Moretz, ScD,S. Lane Slabaugh, PharmD, MBA,Yunus Meah, PharmD,Jean Baltz, MMSc, MSW,Nick C. Patel, PharmD, PhD,Jonathan R. Bouchard, MS, RPh

February 13th 2015

This retrospective cohort study in a Medicare Advantage population posits that type 2 diabetes mellitus complications pose an excess burden on healthcare resource use and related costs.

Latest Updated Articles

Medical Policy Determinations for Pharmacogenetic Tests Among US Health Plans
February 10th 2025
Relationship of Diabetes Complications Severity to Healthcare Utilization and Costs Among Medicare Advantage Beneficiaries
February 13th 2015

Chad Moretz, ScD

Articles by Chad Moretz, ScD

Medical Policy Determinations for Pharmacogenetic Tests Among US Health Plans

Relationship of Diabetes Complications Severity to Healthcare Utilization and Costs Among Medicare Advantage Beneficiaries

Latest Updated Articles

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access